The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.
Aiming to emulate the successful accelerated development of HIV/AIDS drugs, the Critical Path Institute (C-Path), in collaboration with the Engelberg Center for Health Care Reform at the Brookings Institution, has formed the Coalition Against Major Diseases (CAMD). Members include 6 nonprofit groups representing patients' interests, 15 leading pharmaceutical companies, the US Food and Drug Administration (FDA), the European Medicines Agency (EMEA), 2 institutes of the National Institutes of Health (NIH)-the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS)-and representatives from academia. The coalition's purpose is to transform the drug development paradigm for neurodegenerative diseases and serve as a model for other major diseases.
Romero
K
K
Coalition Against Major Diseases, Critical Path Institute, Tucson, Arizona, USA. kromero@c-path.org
de Mars
M
M
Frank
D
D
Anthony
M
M
Neville
J
J
Kirby
L
L
Smith
K
K
Woosley
R L
RL
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers; D035843:Biomedical Research / Q000379:methods*; D018450:Disease Progression; D004345:Drug Industry; D006801:Humans; D007373:Interinstitutional Relations; D010300:Parkinson Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D055818:Public-Private Sector Partnerships
D015415:Biomarkers